2007TSpace (University of Toronto)Open access

Prospective Comparative Trial of Ceftriaxone versus Ceftazidime as Prophylactic Perioperative Antimicrobials in Neurosurgery

Adefolarin O. Malomo, Augustine A. Adeolu, Timothy O. Odebode, EO Komolafe, M T Shokunbi

Open full text 4 citations

Abstract

Background: Previous reports have suggested that both ceftriaxone and ceftazidime are effective as prophylactic perioperative antibiotics in neurosurgery. This study was designed to compare the infection rates following the use of these antibiotics as prophylactic agents during neurological surgery in our centre. In a tertiary hospital Methods: This was a prospective study in which patients were allocated into two groups. One group received ceftriaxone (Roche-rocephine) and the other group received ceftazidime (GlaxoSmithKline - fortum). Patients were followed up for evidence of surgical site infections for up to 6 weeks after discharge. Clinical and or laboratory evidence of wound infection were used as outcome measure. Results: There were 118 patients, 58 patients received ceftriaxone and 60 patients received ceftazidime. Infection occurred in 4 (6.9%) in the ceftriaxone group and in 9 (15%) in the ceftazidime group. The difference was not statistically significant. The infection rate following ventriculoperitoneal (VP) shunting procedure was similar (11.8%) in both groups. Conclusion: Our study confirmed the efficacy of ceftriaxone and ceftazidime in preventing surgical site infection that may follow neurosurgical procedures, but the difference in infection rates following the use of their use was not statistically significant.

Open-access reader

About this research paper

What this paper is about

Background: Previous reports have suggested that both ceftriaxone and ceftazidime are effective as prophylactic perioperative antibiotics in neurosurgery. This study was designed to compare the infection rates following the use of these antibiotics as prophylactic agents during neurological surgery in our centre. In a tertiary hospital Methods: This was a prospective study in which patients were allocated into two groups. One group received ceftriaxone (Roche-rocephine) and the other group received ceftazidime (GlaxoSmithKline - fortum). Patients were followed up for evidence of surgical site infections for up to 6 weeks after discharge. Clinical and or laboratory evidence of wound infection were used as outcome measure. Results: There were 118 patients, 58 patients received ceftriaxone and 60 patients received ceftazidime. Infection occurred in 4 (6.9%) in the ceftriaxone group and in 9 (15%) in the ceftazidime group. The difference was not statistically significant. The infection rate following ventriculoperitoneal (VP) shunting procedure was similar (11.8%) in both groups. Conclusion: Our study confirmed the efficacy of ceftriaxone and ceftazidime in preventing surgical site infection that may follow neurosurgical procedures, but the difference in infection rates following the use of their use was not statistically significant.

Why it matters

OpenAlex reports 4 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Background: Previous reports have suggested that both ceftriaxone and ceftazidime are effective as prophylactic perioperative antibiotics in neurosurgery. This study was designed to compare the infection rates following the use of these antibiotics as prophylactic agents during neurological surgery in our centre. In a tertiary hospital Methods: This was a prospective study in which patients were allocated into two groups. One group received ceftriaxone (Roche-rocephine) and the other group received ceftazidime (GlaxoSmithKline - fortum). Patients were followed up for evidence of surgical site infections for up to 6 weeks after discharge. Clinical and or laboratory evidence of wound infection were used as outcome measure. Results: There were 118 patients, 58 patients received ceftriaxone and 60 patients received ceftazidime. Infection occurred in 4 (6.9%) in the ceftriaxone group and in 9 (15%) in the ceftazidime group. The difference was not statistically significant. The infection rate following ventriculoperitoneal (VP) shunting procedure was similar (11.8%) in both groups. Conclusion: Our study confirmed the efficacy of ceftriaxone and ceftazidime in preventing surgical site infection that may follow neurosurgical procedures, but the difference in infection rates following the use of their use was not statistically significant.

Key concepts: Medicine, Ceftriaxone, Ceftazidime, Perioperative, Neurosurgery, Antibiotics, Surgery, Prospective cohort study

Related papers

Back to paper searchBrowse research topicsOriginal source
Prospective Comparative Trial of Ceftriaxone versus Ceftazidime as Prophylactic Perioperative Antimicrobials in Neurosurgery — Research Paper | ScholarLens